In a nutshell This article reviewed different treatment approaches for patients with advanced Hodgkin's lymphoma (HL). Some background HL is a type of blood cancer of the lymphatic system. HL can be classified in different ways. In limited HL, cancer is found in one or two sites in the lymphatic system. In advanced HL, cancer is found on...
Read MoreTreatment(s) now being considered-Biological therapy Posts on Medivizor
Early 18F-FDG PET/CT response can predict survival in patients with Hodgkin lymphoma treated with nivolumab
In a nutshell This study aimed to investigate if 18F-FDG PET/CT (ePET1) imaging can predict overall survival in patients with relapsed or unresponsive (refractory) Hodgkin lymphoma who have been treated with nivolumab. This study concluded that ePET1 assessment can predict overall survival in these patients. Some...
Read MoreIs targeted therapy more effective than chemotherapy for patients with NSCLC?
In a nutshell This study compared the effectiveness and safety of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy for non-small cell lung cancer (NSCLC). The authors concluded that this combination treatment improved survival outcomes more than chemotherapy. Some background Treatment for NSCLC often includes chemotherapy or...
Read MoreEpidermal growth factor ointment improves the treatment of skin side effects in patients receiving treatment for colorectal cancer
In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with colorectal cancer receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some background...
Read MoreSide effects of ado-trastuzumab emtansine impacting outcomes in patients with HER2+ advanced breast cancer
In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer. This study concluded that these side effects do not impact the outcomes for these patients. Some background...
Read MoreCetuximab improves the outcomes of previously untreated patients with metastatic colorectal cancer
In a nutshell This study investigated the effectiveness of first-line treatment with cetuximab (Erbitux) and bevacizumab (Avastin) in advanced colorectal cancer. Researchers suggested that cetuximab is associated with better outcomes when compared to bevacizumab. Some background Colorectal cancer is the third most common cancer worldwide....
Read MoreLooking for patients with metastatic colorectal cancer to test a combined treatment
In a nutshell This phase 3 trial is examining the effectiveness of a combination treatment with panitumumab (Vectibix), leucovorin and fluorouracil after chemotherapy combined with panitumumab in metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured is progression-free survival (PFS; time from treatment to...
Read MoreEvaluating brentuximab vedotin after alloSCT in patients with recurrent Hodgkin Lymphoma
In a nutshell This study evaluated the outcomes of brentuximab vedotin (Adcetris) treatment for patients with relapsed (recurrent) or progressive (tumor grows or spreads) Hodgkin’s lymphoma (HL) after allogeneic (allo) stem cell transplantation (SCT). This study concluded that brentuximab vedotin is safe and effective for these patients. Some...
Read MoreOral mucositis caused by targeted therapy for colorectal cancer: which drug is safer?
In a nutshell This study investigated the frequency and severity of oral mucositis (OM) in patients with colorectal cancer treated with chemotherapy and panitumumab (Vectibix) or cetuximab (Erbitux). Researchers suggested that panitumumab ?is associated with increased levels of OM in these patients. Some background Colorectal cancer is the fourth...
Read MoreSearching for patients with relapsed/refractory Hodgkin lymphoma to test BV-ICE treatment
In a nutshell This study is investigating the best dose and effectiveness of brentuximab vedotin (Adcetris) combined with ICE (ifosfamide, carboplatin, etoposide) for Hodgkin’s lymphoma (HL) patients with relapsed or refractory (not responding to treatment) disease. The main outcomes to be measured include the tolerated dose without unacceptable...
Read MoreIs pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?
In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read MoreComparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer
In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...
Read More